Alterations in lipid transfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients.
HIV+ patients often develop alterations of the plasma lipids that may implicate in development of premature coronary artery disease. High-density lipoprotein (HDL) has an important role in preventing atherogenesis and the aim of this study was to investigate aspects of HDL function in HIV+ patients. HIV+ patients (n = 48) and healthy control subjects (n = 45) of both sexes with similar age were studied. Twenty-five were not being treated with antiretroviral agents, 13 were under reverse transcriptase inhibitor nucleosidic and non-nucleosidic (NRTI+NNRTI) and 10 were under NRTI + protease inhibitors (NRTI+PI) treatment. Paraoxonase 1 (PON1) activity and the transfer of free and esterified cholesterol, tryglicerides and phospholipids from a lipidic nanoemulsion to HDL were analyzed. In comparison with healthy controls, HIV+ patients presented low PON-1 activity and diminished transfer of free cholesterol and tryglicerides. In contrast, phospholipid transfer was increased in those patients, whereas the transfer of cholesteryl esters was unchanged. NRTI+NNRTI increases the transfer of cholesteryl esters and triglycerides but in NRTI+PI there was no difference in respect to non-treated HIV+ patients. HDL from HIV+ patients has smaller antioxidant properties, as shown by lower PON-1 activity, and the transfer of lipids to this lipoprotein fraction is also altered, suggesting that HDL function is defective in those patients.
Daminelli
Elaine Nunes
EN
Faculty of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Spada
Celso
C
Treitinger
Arício
A
Oliveira
Tatiane Vanessa
TV
Latrilha
Maria da Conceição
Mda C
Maranhão
Raul Cavalcante
RC
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D016022:Case-Control Studies; D002788:Cholesterol Esters / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008075:Lipoproteins, HDL / Q000378:metabolism* / Q000502:physiology; D008297:Male; D010743:Phospholipids / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014280:Triglycerides / Q000378:metabolism
D044966:Anti-Retroviral Agents; D002788:Cholesterol Esters; D017320:HIV Protease Inhibitors; D008075:Lipoproteins, HDL; D010743:Phospholipids; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D043303:Aryldialkylphosphatase